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Abstract: COPD is characterized by progressive airﬂ  ow obstruction which does not fully 
reverse to inhaled or oral pharmacotherapy. The management of patients with COPD has taken a 
totally new direction over the past 20 years, thank to the use of novel therapies aimed to improve 
and modify the natural history of COPD. Long-acting bronchodilators, including long-acting 
β2-agonists (LABAs), were introduced several years ago in order to enhance improvements in 
lung function, health status related quality of life, and reduce the rate of exacerbations. These 
effects can be boosted by the combination of LABAs with long-acting anticholinergic, and/or 
with inhaled corticosteroids. Inhaled LABAs are commonly well tolerated although adverse 
effects such as tremor and palpitations are occasionally troublesome.
Keywords: LABA, COPD, efﬁ  cacy, safety
Introduction
For many years, COPD has been deﬁ  ned as a disorder of airways (inﬂ  ammation) and 
lung parenchyma (destruction) characterized by “poorly reversible” airﬂ  ow limitation 
(American Thoracic Society 1995; Siafakas et al 1995). Airﬂ  ow limitation is deﬁ  ned 
by a FEV1/FVC ratio < 0.7 post-bronchodilator (Pauwels et al 2001; Celli and MacNee 
2004). However, bronchodilators were (and are) consistently reported as the “ﬁ  rst-line 
treatment” of COPD, in patients with airﬂ  ow limitation and symptoms (Pauwels 
et al 2001; Celli and MacNee 2004). There is an apparent contradiction between the 
“poorly reversible” label of the disease in the deﬁ  nition and the indication as “ﬁ  rst-line 
therapy” of drugs whose major action is the reversibility of airﬂ  ow obstruction through 
bronchial smooth muscle relaxation.
In fact, many recent studies have shown that signiﬁ  cant reversibility of the airﬂ  ow 
limitation can be detected in about half of patients with moderate-to-severe COPD 
recruited for clinical trials. Furthermore, it has been systematically observed that 
regular treatment of COPD patients with bronchodilators improve symptoms such 
as dyspnea and exercise tolerance (Rennard and Calverley 2006). In the more recent 
international documents (Celli and MacNee 2004), the expression “poorly reversible” 
has been replaced by “not completely reversible” and the deﬁ  nition has been reviewed 
such that now COPD is described as a “treatable and preventable” disease.
From “negative” to “positive” approach
The new “positive” attitude toward COPD, leaving the “negative” (sometimes called 
nihilistic) approach to the past, is the result of many clinical studies, which have 
documented how pharmacologic and non-pharmacologic treatments for patients with 
moderate-to-severe COPD can be effective in improving the patient’s health status and 
in preventing exacerbations of the disease (Celli and MacNee 2004). As previously 
mentioned, several clinical trials have shown that some degree of reversibility of the 
airﬂ  ow limitation is not uncommon in patients with COPD and that the regular treatment International Journal of COPD 2008:3(4) 522
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with long-acting bronchodilators has favorable outcomes in 
those patients (Cazzola and Dahl 2004; Tashkin and Cooper 
2004; Rennard and Calverley 2006).
The clinical studies failed to ﬁ  nd any relationship between 
the acute and long-term response to inhaled bronchodilators. 
It is widely recognized that the change in FEV1 after an 
acute bronchodilatation test does not predict either the long-
term effect of the regular bronchodilating treatment nor the 
perception of improvement by the patients (Celli and Mac-
Nee 2004). Therefore, the “poor reversibility” of an acute 
bronchodilating test cannot be used to exclude patients from 
the beneﬁ  ts of long term treatment. It has been shown that the 
response to the bronchodilating therapy may develop after 
two weeks of treatment or even more. The guide for therapy 
is not the change in FEV1, but the relief from symptoms and 
particularly the reduction of dyspnea and the improvement in 
the exercise tolerance. The latter can be easily assessed not 
only by listening to the patients but also, at least for clinical 
purposes, by means of the 6 minutes walking test. This is 
a simple investigation, easy to perform in the clinical set-
tings and approximately predictive of the patients’ exercise 
capacity. The grade of chronic dyspnea can be measured by 
means of the MRC (medical research council) scale (Celli 
et al 2004).
Classes of bronchodilators
Among bronchodilators, short-acting agents, such as 
salbutamol, fenoterol, terbutaline, and ipratropium, have 
been abandoned for the regular therapy of COPD patients 
and are suggested only for rapid symptom relief as rescue 
medication. This approach has been adopted from the Asthma 
guidelines and becomes useful for COPD mainly when 
an exacerbation begins. Long-acting bronchodilators are 
indicated for regular treatment of symptomatic patients with 
moderate-to-severe COPD. The long-acting agents include 
two classes of drugs:
• the  long-acting  β2-agonists (LABAs), eg, salmeterol and 
formoterol;
•  the anticholinergics, eg, tiotropium.
Formoterol and salmeterol are both long-acting 
bronchodilators that are effective in the treatment of 
asthma (Lötvall 2001). After single doses, clear effects 
are maintained for 12 h after inhalation and with high 
doses, effects are observed even at 24 h. However, some 
differences exist in their pharmacology that are reﬂ  ected in 
their clinical proﬁ  les. Formoterol has a rapid onset of action, 
whereas salmeterol causes bronchodilation in a somewhat 
slower manner. Moreover, formoterol has a higher intrinsic 
activity than salmeterol, which means that it is a full agonist, 
whereas salmeterol is a partial agonist of β2-adrenoceptor. 
Physicochemical properties of the drugs may explain the 
differences in onset and duration of action. Adequate water 
solubility and moderate lipophilicity of formoterol ensures 
rapid diffusion to the β2-adrenoceptor on the smooth muscle 
and rapid bronchodilating activity. Salmeterol, on the other 
hand, may diffuse more slowly to the β2-adrenoceptor because 
of its high lipophilicity, explaining the slower onset of action. 
Unlike salbutamol, which is hydrophilic and has a rapid onset 
and short duration of action, both formoterol and salmeterol 
possess adequate lipophilic properties to remain in the airway 
tissues as a depot in close vicinity of the β2-adrenoceptors, 
explaining their long duration of effect. The long duration of 
salmeterol has also been suggested to depend on an anchored 
binding within the β2-adrenoceptor.
The available data on LABA come from studies lasting 
1 year or less (Man et al 2003; Sin et al 2003; Sutherland and 
Cherniack 2004). Only recently a 3-year prospective study 
(the TORCH study) has been published (The TORCH Study 
Group 2004; Calverley et al 2007). In that study, an arm was 
represented by therapy with salmeterol for 3 years. A longer 
study (4 years), namely the “Understanding Potential Long-
Term Impacts on Function with Tiotropium” – UPLIFT, 
is still in progress, and the data will be available in 2008. 
This study is based on the long-acting anticholinergic agent, 
tiotropium (Rabe 2007). Another 4-year study was carried 
out some years ago on the short-acting anticholinergic agent 
ipratropium bromide (Anthonisen et al 1994). That study 
failed to show any effect of ipratropium bromide on the 
progression of COPD, measured by means of the annual 
decline of FEV1, compared with placebo.
In this article only LABAs are considered. LABAs are 
more effective with fewer side effects than theophylline 
(Rossi et al 2002). Theophylline was the common therapy 
for COPD before LABAs were introduced, though its use is 
still not negligible in western countries. Theophylline is still 
commonly used in some countries, mainly Asiatic, where for 
economic reasons it remains the preferred bronchodilator. 
A few studies encourage the association of LABA with 
theophylline (Rennard and Calverley 2006). However, the 
association of LABA with long-acting anticholinergics seems 
more promising (Cazzola et al 2004; Van Noord et al 2005; 
Van Noord et al 2006; Aaron et al 2007).
LABAs in COPD
The role of long-acting bronchodilators, both LABAs and 
tiotropium, in the management of COPD is well established International Journal of COPD 2008:3(4) 523
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and graded with evidence A in the national and international 
guidelines documents (Pauwels et al 2001; Kottakis et al 
2002; Celli and MacNee 2004). In fact, several prospective 
randomized trials and a high quality meta-analysis (Man 
et al 2003; Sin et al 2003) have shown that LABAs 
improve lung function and health status related quality 
of life, and reduce exacerbations in symptomatic patients 
with moderate-to-severe COPD. The improvement in lung 
function, measured by means of the baseline change in 
FEV1 is rather small, amounting on average to 100–150 mL. 
However, it is statistically signiﬁ  cant and it is associated with 
an improvement in the patient’s condition and health status 
perception. Moreover, LABAs have the potential to improve 
the mucociliary component of COPD. In combination with 
an inhaled corticosteroid, mucociliary clearance is indirectly 
improved by the presence of important anti-inﬂ  ammatory 
activity (Rogers 2005).
The studies on LABAs up to 1 year failed to show any 
effect of the treatment on the progression of COPD, measured 
by means of the rate of decline of FEV1. Interestingly, all 
trials failed also to ﬁ  nd any correlation between the improve-
ment in symptoms and in FEV1. The lack of this relationship 
raises the question about the mechanism through which 
LABA can determine an improvement in the health status.
LABAs, airﬂ  ow limitation,
and pulmonary hyperinﬂ  ation
It is well known that smoking cessation modiﬁ  es the natural 
history of COPD by reducing signiﬁ  cantly the progressive 
decline in FEV1 (Petty 2006) and even mortality (Anthonisen 
et al 2005). By contrast, LABAs improve lung function 
but do not reduce the faster annual rate of decline of FEV1 
in COPD patients compared with smokers without COPD 
and non-smokers (Man et al 2003; Sin et al 2003). This 
conclusion, coming from the 1-year or shorter clinical trials, 
has been challenged by the results of the TORCH study, 
which showed a greater rate of the decline of FEV1 in the 
placebo arm compared with the salmeterol arm (The TORCH 
Study Group 2004; Calverley et al 2007). The data are even 
more convincing if the salmeterol-ﬂ  uticasone combination 
arm is compared with placebo after 3 years of treatment (see 
below). The data from the TORCH study suggest that regular 
pharmacologic therapy for COPD may actually change the 
natural history of the disease by slowing the progressive 
decline in the lung function.
Regular treatment with LABA reduces the rate of 
exacerbations by 22% on average (Man et al 2003; Sin 
et al 2003) and improves the health status and quality of 
life (Man et al 2003; Sin et al 2003). A robust hypothesis 
is that the improvement in the heath status related quality 
of life, usually assessed by means of the St George 
Respiratory Questionnaire, is determined by the reduction 
of breathlessness and the increase in the exercise capacity 
due to the decrease of dynamic lung hyperinﬂ  ation after 
bronchodilatation (Cooper 2006).
Small airways in COPD
Three landmark studies (Hogg et al 1968, 2004; Cosio et al 
1978; Hogg 2004), among others, documented that small 
airways are the major site of airﬂ  ow limitation in COPD 
(Macklem 1998b; Hogg 2004). The pathologic changes in 
the lungs of patients with COPD show secretions in the 
bronchial lumen, inﬂ  ammatory inﬁ  ltrate in the bronchial 
wall, and loss of alveolar attachments (Barnes 2004). These 
pathologic modiﬁ  cations are mainly located in the small 
airways. The airway smooth muscle layer, which is the 
target of the bronchodilating agents, is neither hypertro-
phic nor hyperplastic. In the small airways, the bronchial 
wall is thick. These changes are very different in asthma, 
where the smooth muscle layer in the small airways is 
much thicker than normal. The contraction of the smooth 
muscle in the inﬂ  ammatory environment of the bronchial 
wall is the mechanism causing airﬂ  ow obstruction in 
asthma. By contrast, the airﬂ  ow limitation in COPD does 
not seem to be particularly related to the action of the 
contractile machinery but rather to the loss of lung elastic 
recoil, to the destruction of the alveolar attachments, and 
to the dynamic compression of the small airways during 
expiration (Hogg 2004). However, the signiﬁ  cant and per-
sistent, though apparently small, improvement in the FEV1 
reported by all the clinical trials (Man et al 2003; Sin et al 
2003) indicates that part of the impediment to expiration is 
determined by bronchial smooth muscle contraction, and 
that it is removed by the smooth muscle relaxing agents 
such as LABAs.
Airway smooth muscle relaxation through β2-adrenoceptor 
stimulation, leading to an increase in cyclic adenosine 
mono-phosphate, improves airway patency and provides 
also a signiﬁ  cant relief from exercise dyspnea (Rennard 
and Calverley 2006). Interestingly, the improvement in the 
exercise capacity of COPD patients was not found to be 
related to changes in FEV1 but to an increase in the inspira-
tory capacity (IC), mirroring a decrease in the functional 
residual capacity (FRC) (Cooper 2006). These results 
provide an insight into the mechanism through which 
LABAs relief dyspnea.International Journal of COPD 2008:3(4) 524
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Pulmonary hyperinﬂ  ation
Although it was known for many years that retarded 
expiration due to increased airway resistance and airﬂ  ow 
limitation causes an increase in FRC (Macklem 1998a), the 
key role of pulmonary hyperinﬂ  ation in the pathophysiology 
of COPD was brought to the attention of clinical practice 
more recently (Rossi et al 1991; Cooper 2006). This issue 
is discussed extensively elsewhere (Calverley and Koulouris 
2005). Brieﬂ  y, increased airway resistance and expiratory 
airﬂ  ow limitation retard the rate of expiratory ﬂ  ow such 
that the tidal expiration is not completed to the relaxed FRC 
because of the excessive time needed and the new inspiratory 
effort ensues. Under those circumstances, tidal FRC remains 
above the relaxed FRC and dynamic hyperinﬂ  ation occurs 
because of the discrepancy between the time needed to fully 
decompress the lungs and the time actually available between 
two next inspiratory efforts.
The smooth muscle relaxing agents, as LABAs, improve 
the small airway patency and hence the rate of lung emptying 
such that following bronchodilatation, dynamic FRC is set at 
a lower lung volume than the pre-bronchodilatation condition. 
Breathing at a lower FRC decreases the work of breathing 
while placing the respiratory muscle in a more favorable 
geometric arrangement for their pressure generating capacity 
(Man et al 2004; Gayan-Ramirez et al 2006). The association 
of the decrease in the work of breathing with a better 
ventilatory pump performance determines the improvement 
in exercise tolerance and the reduction of dyspnea.
Only a few papers have addressed the effect of LABAs 
on pulmonary hyperinflation (Di Marco et al 2003; 
O’Donnell et al 2004). However, the data are consistent 
for both salmeterol and formoterol (Di Marco et al 2003; 
O’Donnell et al 2004). It has been shown that the “small” 
bronchodilatation is associated with a signiﬁ  cant reduction 
of FRC with a mirror increase in IC. The latter is inversely 
correlated with dyspnea (assessed by means of the Visual 
Analog Scale [VAS], the Borg scale or the Baseline [BDI] 
and Transition [TDI] Dyspnoea Indexes) and it is positively 
correlated with exercise capacity (Cooper 2006). IC provides 
the inspiratory reserve when minute ventilation increases 
to meet the greater metabolic demand during exercise. 
Therefore, a larger IC allows a greater exercise capacity 
(Diaz et al 2000; O’Donnell et al 2001). Furthermore, 
the decrease in FRC increases the distance between tidal 
breathing and the total lung capacity (TLC). The upper 
limit for ventilation is reached when about 0.5 L divides 
the end-inspiratory volume from TLC (Diaz et al 2000; 
O’Donnell et al 2001).
LABAs and anticholinergics
Combining β2-agonists and anticholinergic agents is 
pharmacologically useful. In fact, the addition of a β2-agonist 
decreases the release of acetylcholine because of the 
modulation of cholinergic neurotransmission by prejunctional 
β2-adrenoceptors and, consequently, ampliﬁ  es the bronchial 
smooth muscle relaxation directly induced by the anticholinergic 
agent. Alternatively, the addition of an anticholinergic agent 
can reduce the peripheral bronchoconstrictor effects of 
acetylcholine, whose release has been slowed by the β2-agonist, 
and in this manner it can amplify the bronchodilation elicited 
by the β2-agonist through the direct stimulation of smooth 
muscle β2-adrenoceptors (Cazzola and Matera 2006).
Some studies on the acute effect of LABAs in association 
with tiotropium have shown that the combination of the two 
drugs generates a greater bronchodilatation than either alone 
(Cazzola and Matera 2006). One recent prospective, random-
ized clinical trial addressed the issue of combined therapy 
in patients with moderate-to-severe COPD. Patients were 
randomly divided into 3 arms of treatment and followed for 1 
year. One-third of patients received tiotropium plus placebo, 
one-third received tiotropium plus LABA (salmeterol), and 
one-third received tiotropium plus the salmeterol-ﬂ  uticasone 
ﬁ  xed combination (SFC). The addition of salmeterol to 
tiotropium did not signiﬁ  cantly improve the predetermined 
outcomes. By contrast, the addition of SFC to tiotropium 
signiﬁ  cantly improved lung function, with an increase in 
FEV1 of 110 mL on average, and on health status related 
quality of life. The addition of either salmeterol or SFC to 
tiotropium failed to show any effect on the rate of exacerba-
tions, but the addition of SFC to tiotropium reduced the num-
ber of hospitalizations. Another recent study in severe-to-very 
severe COPD has observed that improvement in pulmonary 
function, expressed as a change in FEV1, did not differ 
between tiotropium and SFC, but the simultaneous admin-
istration of the two treatments provided greater improve-
ments in FEV1 compared with the other two therapeutic 
regimens taken separately (Cazzola et al 2007a). This is an 
intriguing result, but the study does not allow to establish if 
the improvement in lung function caused by combining SFC 
and tiotropium was linked to the effect of the combination of 
two long-acting bronchodilators or due to a synergistic inter-
action between the inhaled corticosteroid and the long-acting 
bronchodilators, with the resulting synergetic effect being 
greater than the sum of responses achieved from each drug 
alone. Interestingly, a recent study has documented that the 
addition of theophylline on a combination of formoterol and 
tiotropium in stable COPD did not induce a signiﬁ  cant further International Journal of COPD 2008:3(4) 525
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improvement in lung function and dyspnea, although 5 out of 
18 patients reported an important relief in dyspnea during the 
theophylline administration period. This ﬁ  nding questions the 
importance of adding theophylline in stable COPD patients 
already treated with two long-acting bronchodilators, but 
also indicates the possibility that some of them can beneﬁ  t 
from theophylline because of a symptomatic improvement 
(Cazzola and Matera 2007).
LABAs in COPD guidelines
National and international guidelines (British Thoracic 
Society 2004; Celli and MacNee 2004; Rabe et al 2007) 
suggest that long-acting bronchodilator therapy should 
always be considered when patients with COPD are 
symptomatic, but no distinction is made as to which class 
of drug should be considered ﬁ  rst, although β2-agonists and 
anticholinergics are distinct classes of drugs with different 
mechanisms of action. This is the likely reason for which 
Tennant et al (2003) suggest that individual COPD patients 
may respond better to either tiotropium or salmeterol and 
that an acute bronchodilator test might help to choose the 
appropriate therapy. However, it has been documented that 
the bronchodilator effects of tiotropium and salmeterol, 
evaluated as mean changes from baseline FEV1, are similar 
in patients with stable COPD during the ﬁ  rst 3 hours after 
their acute administration, and consequently the choice 
of prescribing a long-term therapy with a long-acting 
bronchodilator should not depend on the simple test of 
reversibility (Matera et al 2005). In any case, the GOLD 
treatment recommendations for patients with stable COPD 
are characterized by a stepwise increase in therapy according 
to disease severity (Rabe et al 2007). Table 1 illustrates two 
possible pathways for the regular use of inhaled therapies 
with increasing COPD severity. The ﬁ  rst column repre-
sents an evidence-based rationale for the utilization of 
inhaled therapies in COPD according to the GOLD execu-
tive document, while the second column shows the ACP 
recommendation (Qaseem et al 2007), which considers only 
the treatment of symptomatic patients. Historically, severity 
of COPD has been classiﬁ  ed according to FEV1, but FEV1 
may not correlate directly with symptoms and, consequently a 
symptomatic approach to therapy using clinical stages may be 
more useful. Consequently, the ATS/ERS COPD guidelines 
(Celli and MacNee 2004) have indicated the importance of 
starting regular maintenance therapy based on the presence 
of persistent symptoms, regardless of the disease stage. 
The choice of agents may be based primarily on individual 
response, cost, side-effect proﬁ  le and availability.
Nonetheless, Cooper and Tashkin (2005) have described 
a more explicit and practical patient oriented approach to the 
hierarchical implementation of pharmacotherapy in COPD. 
They have proposed a clinical treatment algorithm based 
on the clinical stage of disease regardless of disease stage 
or lung function. For patients with intermittent symptoms, 
as-needed use of a short-acting bronchodilator (eg, ipratro-
pium, salbutamol or both) is recommended. For patients with 
persistent symptoms, maintenance treatment should be initi-
ated with a long-acting bronchodilator, preferably tiotropium 
added to salbutamol (suitable alternatives are salmeterol or 
formoterol added to salbutamol and/or ipratropium, or both); 
salbutamol should be continued as needed for rescue from 
symptoms. The ﬁ  nal treatment step for patients with frequent 
exacerbations or inadequate control of symptoms, despite 
optimal bronchodilator therapy, is a LABA in combination 
with a long-acting anticholinergic agent, with or without the 
addition of inhaled corticosteroids.
Adverse effects of LABA
A recent meta-analysis concluded that treatment with LABAs 
could be associated with worsening of disease control 
(Salpeter et al 2006b). Salpeter and colleagues (2004) found 
that the use of LABA, in COPD patients, did not affect 
severe exacerbations, but resulted in a signiﬁ  cant increase 
of respiratory deaths compared with placebo. The addition 
of LABAs to anticholinergics did not improve any clinical 
outcome in that meta-analysis.
The conclusion on the dangerous consequence of regular 
treatment with salmeterol in patients with COPD was not 
conﬁ  rmed and was opposed, to some extend, by the results of 
other studies in which LABAs were compared with placebo, 
inhaled corticosteroids (ICS), both ﬂ  uticasone (Calverley 
et al 2003b) and budesonide (Centanni and Di Marco 
2005; Cazzola and Hanania 2006), and the combination of 
salmeterol-ﬂ  uticasone and formoterol-budesonide (Calverley 
et al 2003a; Szafranski et al 2003; Cazzola and Dahl 2004). 
The three prospective, randomized trials (Calverley et al 
2003a, b; Szafranski et al 2003) showed a beneﬁ  cial effect 
of salmeterol or formoterol compared to placebo and an 
additional beneﬁ  cial effect of the ICS-LABA combination 
compared to both placebo or LABA alone for any of the 
considered outcomes. Lung function and quality of life were 
better and the rate of exacerbations was reduced (Man et al 
2003; Sin et al 2003).
These results are in line with a more recent three-year 
large prospective randomized trial (over 6000 COPD 
patients), ie, the TORCH study (The TORCH Study Group International Journal of COPD 2008:3(4) 526
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2004; Calverley et al 2007), in which the effects of salmeterol 
for all the considered variables were compared with the 
placebo and the SFC arms. After 3 years of treatment, the 
group of patients treated with salmeterol had a signiﬁ  cantly 
better lung function and health related quality of life than 
the placebo group. The COPD patients treated with the SFC 
exhibited even better results than both single components 
and placebo. Furthermore, the mortality for all causes and 
for respiratory causes in the salmeterol arm was lower, 
though not signiﬁ  cantly, than in the placebo arm. This large 
3-year trial, therefore, in line with the previously mentioned 
shorter clinical trials, does not support the conclusion of the 
meta-analysis undertaken by Salpeter et al (2006b) whereas 
it supports the regular use of a LABA in COPD patients. 
The TORCH study, similarly to the previous clinical trial on 
salmeterol and SFC, did not report any adverse event related 
to the treatment with the LABA. In particular, no increase in 
the rate of death was observed. Also the prospective one-year 
study in which salmeterol or SFC were added randomly to 
tiotropium failed to show any adverse effect related to the 
use of the LABA (Aaron et al 2007).
LABAs and cardiovascular effects
A recent meta-analysis addressed the issue of cardiovascular 
effects of β-agonists in patients with obstructive airway dis-
eases, ie, asthma and COPD (Salpeter et al 2006a), and found 
that initiation of β2-agonists therapy was associated with 
signiﬁ  cant increase in heart rate and reductions in potassium 
concentrations. With continuous treatment, the rate of 
cardiovascular events was increased compared to placebo. 
The authors concluded that regular treatment with β2-agonists 
could precipitate arrhythmias, ischemia, and congestive heart 
failure through the activation of β-adrenergic stimulation 
(Salpeter et al 2004; Salpeter et al 2006a). Clearly, the meta-
analysis has severe limitations and the conclusion cannot be 
taken as deﬁ  nitive. In fact there is a marked heterogeneity 
among trials in terms of length, selected population, number 
of patients and documentations of adverse events.
It is well known that LABAs may cause adverse 
cardiovascular effects (Salpeter et al 2004; Cazzola et al 
2005; Salpeter et al 2006b). β-agonists cause palpitation, 
hypokalemia, and occasionally ventricular arrhythmias 
(Cazzola et al 2005). These effects are due to systemic 
absorption of the drug as a result of both the lung deposition 
and the swallowed portion.
LABAs are selective β2-adrenoceptor agonists. β1- and 
β2-adrenoceptors coexist in the heart, though β1-adrenoceptor 
density is 3-fold higher than that of β2-adrenoceptors.The 
presence of β2-adrenoceptors in the heart explains why 
β2-agonists can induce a number of adverse effects that poten-
tially impact on cardiac function. These effects are usually 
considered to be mild. In any case, it has been shown that 
full β2-agonists would elicit a greater response than partial 
agonists (Hanania et al 2002).
Salmeterol and formoterol have similar effects. However, 
in patients suffering from COPD with pre-existing cardiac 
arrhythmias and hypoxemia, the cardiac effects of formoterol 
24 μg bid are more marked (Cazzola et al 1998). Cazzola et al 
(1998) concluded that 50 μg bid of salmeterol and 12 μg bid 
of formoterol have a reasonable safe margin in this type of 
Table 1 Pharmacological treatment of stable COPD
GOLD stage GOLD key-points ACP recommendations
FEV1/FVC  0.70
FEV1  80% pred (I)
Short-acting bronchodilators as needed
FEV1/FVC  0.70
50%  FEV1  80% pred (II)
Long-acting bronchodilators
+
Short-acting bronchodilators as needed
FEV1/FVC  0.70
30%  FEV1  50% pred (III)
Combination of long-acting bronchodilators
+
Short-acting bronchodilators as neededb
Long-acting bronchodilators or Inhaled 
corticosteroids or Combination inhaled 
therapiesc
FEV1/FVC  0.70
FEV1  30% pred or FEV1  50% pred plus 
chronic respiratory failurea (IV)
Combination of long-acting bronchodilators
+
Inhaled corticosteroids
aRespiratory failure: arterial partial pressure of oxygen (PaO2)  8.0 kPa (60 mmHg) with or without arterial partial pressure of CO2 (PaCO2)  6.7 kPa (50 mmHg) while 
breathing air at sea level.
bInhaled corticosteroids are indicated in case of repeated exacerbations requiring treatment with antibiotics or oral glucocorticoids or if positive response (decreased symptoms, 
increased lung function, and/or reduced health-care utilization).
cFor symptomatic patients with COPD and FEV1  60% predicted (Qaseem et al 2007).
Abbreviation: ACP,  American College of Physicians.International Journal of COPD 2008:3(4) 527
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COPD patients. Nonetheless, other authors failed to show any 
signiﬁ  cant difference on the electrocardiogram between placebo 
and salmeterol (Reisner et al 2003). Heart disease is not currently 
regarded as a contraindication to cautious use of β2-agonists in 
COPD patients (Rennard and Calverley 2006).
Some reports suggest the presence of an association 
between β2-agonists and the risk of chronic heart failure. The 
sympathetic nervous system and pro-inﬂ  ammatory cytokines 
are believed to play a key-role in the pathophysiology of 
congestive heart failure and chronic β-adrenergic stimula-
tion has shown to induce myocardial pro-inﬂ  ammatory 
cytokine expression (Murray et al 2000). However, Ng et al 
(2002) found that a long-term inhaled salmeterol therapy 
(100 μg twice daily) improved pulmonary function, without 
augmentation of neurohormonal systems or ventricular 
ectopy, in symptomatic heart failure patients with a left 
ventricular ejection fraction of less than 40%.
It must be highlighted, in any case, that COPD patients 
are at increased risk of cardiovascular complications. This 
might be due to the effects of the smoking practice which 
affects both the cardiovascular and the respiratory system. 
On the other hand, COPD ampliﬁ  es the impact of β2-agonist 
on the heart. In patients with COPD, the activity of the 
cardiac sympathetic nerves may be affected by recurrent 
hypoxemia, hypercapnia, changes in airway tone, increased 
intrathoracic pressure as a result of airway obstruction, and 
large ﬂ  uctuations in heart rate and blood pressure due to 
increased respiratory effort (Zimmer et al 2000). Patients 
with hypoxemic COPD, in particular, have been reported 
to have subclinical autonomic neuropathy associated with a 
prolonged QTc interval and an associated risk of ventricu-
lar arrhythmias (Stewart et al 1995). The existence of left 
ventricle myocardial sympathetic nervous alterations as a 
result of generalised sympathetic autonomic nervous system 
over activity has been suggested (Sakamaki et al 1999).
Impact of LABAs on blood gases
It is known that the administration of β-adrenergic agents to 
patients with airways obstruction often results in a transient 
decrease in partial pressure of oxygen in arterial blood 
(PaO2) despite concomitant bronchodilation (Cazzola et al 
2006). The clinical relevance of changes in oxygenation may 
be considerable for patients with COPD because ﬁ  ndings 
reflecting bronchodilation do not necessarily correlate 
with the perception of breathlessness, but, apparently, both 
formoterol and salmeterol result in signiﬁ  cant improvement 
in lung function and signiﬁ  cant but small decreases in PaO2 
and increases in P(A-a)O2 (Santus et al 2007). In any case, the 
average changes are quite small and of questionable clinical 
signiﬁ  cance. The transient decrease in PaO2 with β-adrenergic 
agents has been attributed to the pulmonary vasodilator action 
of these agents due to the activation of β-adrenoceptors that 
are present in pulmonary vessels (Cazzola et al 2007b), 
increasing blood ﬂ  ow to poorly ventilated lung regions and 
thus increasing ventilation-perfusion (VA/Q) inequality, 
inducing a shunt-like effect (Wagner et al 1978).
Conclusions
Long-acting bronchodilators are the ﬁ  rst-line treatment of 
symptomatic (poor exercise tolerance) patients with COPD. In 
this class of drugs, LABAs (salmeterol and formoterol) have 
a key-role in the pharmacologic therapy of COPD. LABAs 
improve lung function and health status related quality of 
life, and reduce the rate of exacerbations. These effects can 
be enhanced by the combination of LABAs with tiotropium, 
and with inhaled corticosteroids. An additional beneﬁ  t can be 
reached by combining the three drugs in the treatment. LABAs 
may have adverse cardiovascular effects, which are ampliﬁ  ed 
in COPD patients with concomitant cardiac disorders. In 
these patients, LABAs should be used with some cautions. 
At the present level of our knowledge, the use of LABAs 
in COPD patients, even patients with cardiac disease comor-
bidity, does not put “caveats” similar to the use of LABAs in 
asthma. This might be considered to some extent surprising, 
because COPD patients are older than patients with asthma 
and have a larger comorbidity for cardiac disorders. COPD 
patients with cardiac comorbidity may be treated with both 
β-blockers and β-agonists at the same time.
The important message from many recent and large 
clinical trials is that COPD patients should be treated with 
inhalation drugs. LABAs, tiotropium, and LABA plus ICS 
combinations are available and can be used either separately 
or in association. Patients taking regular bronchodilating 
therapy have a better quality of life than patients who do 
not take regular bronchodilating medications. The potential 
adverse cardiovascular effects of LABAs and the presence 
of cardiac comorbidity in COPD patients suggest caution but 
do not represent a contraindication.
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